TSNLF (Tristel) ROCE %: 26.15% (As of Dec. 2025)

What is Tristel ROCE %?

Tristel TSNLF +6.35% 97 ROCE % is 26.15% as of Dec. 2025. GuruFocus rates TSNLF with a GF Score™ of 97/100 and a GF Value™ of $6.13 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tristel's annualized ROCE % for the quarter that ended in Dec. 2025 was 26.15%.

Tristel (OTCPK:TSNLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tristel ROCE % Related Terms

Tristel ROCE % Historical Data

* Premium members only.

The historical data trend for Tristel's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tristel ROCE % Chart

Tristel Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

ROCE %

Get a 7-Day Free Trial

11.63

4.49

15.12

20.04

23.69

Tristel Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															19.51	20.62	20.35	26.85	26.15

97GF Score

Tristel PLC TSNLF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tristel ROCE % Calculation

Tristel's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	11.771	/	( ( (56.118 - 8.387)	+	(61.512 - 9.858) )	/ 2 )
	=	11.771	/	( (47.731	+	51.654)	/ 2 )
	=	11.771	/	49.6925
	=	23.69 %

Tristel's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	13.588	/	( ( (61.512 - 9.858)	+	(60.822 - 8.565) )	/ 2 )
	=	13.588	/	( ( 51.654	+	52.257 )	/ 2 )
	=	13.588	/	51.9555
	=	26.15 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 26.15% mean?

Tristel (TSNLF) has a ROCE % of 26.15% as of Dec. 2025.

Is Tristel's ROCE % too high?

Tristel's current ROCE % is 26.15%. The Medical Devices & Instruments industry median ROCE % is 2.23. Tristel's value of 26.15% is 1072.6% above this industry median. Overall, Tristel has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Tristel's ROCE % compare to ISRG and BDX?

Tristel's ROCE % of 26.15% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Tristel's value of 26.15% is 1072.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current ROCE % of 26.15% is 1072.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current ROCE % is 26.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tristel stock overvalued right now?

Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.13, compared to a current price of $5.53 — trading 9.8% below its estimated fair value. The current ROCE % is 26.15% and 1072.6% above the Medical Devices & Instruments industry median of 2.23. Tristel's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Tristel (TSNLF), the current ROCE % is 26.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tristel (TSNLF) Overvalued in 2026?

Based on GuruFocus' analysis, Tristel stock appears to be undervalued. The current stock price of $5.53 is trading 9.8% below its estimated GF Value™ of $6.13. GuruFocus considers Tristel to be Modestly Undervalued.

Key valuation signals for TSNLF:

ROCE %: 26.15%
GF Value™: $6.13 vs. price of $5.53 (9.8% below fair value)
GF Score™: 97/100 with 1 warning sign
Industry Position: 1072.6% above the Medical Devices & Instruments median

No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tristel Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies LSE:SPEC LSE:BVC LSE:CNSL LSE:AMS ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM XSWX:STMN XTER:SRT OCSE:COLO B NZSE:FPH SOLV ALGN

Other Exchanges TSTL:UK R1V:Germany

Address Fordham Road, Unit 1B, Lynx Business Park, Newmarket, Snailwell, Cambridgeshire, GBR, CB8 7NY

Website https://www.tristel.com

Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.

97GF Score

Get the complete analysis for TSNLF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.53

Price

$6.13

GF Value

View TSNLF Analysis

See ROCE % data for all stocks →